Joseph Schwartz
Stock Analyst at Leerink Partners
(4.08)
# 500
Out of 5,154 analysts
154
Total ratings
34.78%
Success rate
20.03%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Joseph Schwartz
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| GOSS Gossamer Bio | Downgrades: Market Perform | $6 → $1 | $0.50 | +99.72% | 8 | Feb 24, 2026 | |
| RARE Ultragenyx Pharmaceutical | Maintains: Outperform | $80 → $70 | $21.25 | +229.41% | 7 | Dec 30, 2025 | |
| FOLD Amicus Therapeutics | Downgrades: Market Perform | $17 → $15 | $14.34 | +1.12% | 13 | Dec 29, 2025 | |
| SPRB Spruce Biosciences | Upgrades: Outperform | $160 | $55.87 | +186.38% | 7 | Dec 3, 2025 | |
| DSGN Design Therapeutics | Upgrades: Outperform | $7 → $14 | $10.05 | +39.30% | 5 | Dec 3, 2025 | |
| IFRX InflaRx | Downgrades: Market Perform | $5 → $2 | $0.97 | +106.19% | 5 | Dec 3, 2025 | |
| BMRN BioMarin Pharmaceutical | Downgrades: Market Perform | $82 → $60 | $61.12 | -1.83% | 11 | Dec 3, 2025 | |
| AUPH Aurinia Pharmaceuticals | Downgrades: Market Perform | $15 → $16 | $14.32 | +11.73% | 7 | Dec 3, 2025 | |
| QURE uniQure | Maintains: Outperform | $68 → $60 | $14.27 | +320.46% | 3 | Nov 10, 2025 | |
| MNPR Monopar Therapeutics | Initiates: Outperform | $115 | $57.47 | +100.10% | 1 | Nov 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $80 → $88 | $38.23 | +130.19% | 2 | Sep 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $12 → $15 | $16.71 | -10.23% | 14 | Sep 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $18 → $20 | $16.23 | +23.23% | 6 | Jul 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $100 → $115 | $140.13 | -17.93% | 4 | Jun 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $4 → $12 | $8.17 | +46.88% | 4 | May 23, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $28 | $44.83 | -37.54% | 1 | Feb 25, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $20 → $40 | $27.24 | +46.84% | 6 | Oct 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | n/a | $2.85 | - | 3 | Jul 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $12 | $6.75 | +77.78% | 6 | Jun 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $6 → $8 | $0.39 | +1,929.94% | 2 | Jun 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Market Perform | $48 | $62.82 | -23.59% | 1 | Mar 17, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $20 → $18 | $25.91 | -30.53% | 5 | Feb 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $33 → $34 | $74.04 | -54.08% | 1 | Feb 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $148 → $163 | $240.65 | -32.27% | 15 | Jan 17, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $40 → $33 | $5.69 | +480.47% | 2 | Nov 10, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | $64 → $52 | $10.16 | +411.81% | 5 | Aug 5, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $34 → $30 | $27.82 | +7.84% | 2 | May 12, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $50 → $30 | $92.09 | -67.42% | 6 | May 5, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $10 → $12 | $1.78 | +574.16% | 2 | Sep 26, 2017 |
Gossamer Bio
Feb 24, 2026
Downgrades: Market Perform
Price Target: $6 → $1
Current: $0.50
Upside: +99.72%
Ultragenyx Pharmaceutical
Dec 30, 2025
Maintains: Outperform
Price Target: $80 → $70
Current: $21.25
Upside: +229.41%
Amicus Therapeutics
Dec 29, 2025
Downgrades: Market Perform
Price Target: $17 → $15
Current: $14.34
Upside: +1.12%
Spruce Biosciences
Dec 3, 2025
Upgrades: Outperform
Price Target: $160
Current: $55.87
Upside: +186.38%
Design Therapeutics
Dec 3, 2025
Upgrades: Outperform
Price Target: $7 → $14
Current: $10.05
Upside: +39.30%
InflaRx
Dec 3, 2025
Downgrades: Market Perform
Price Target: $5 → $2
Current: $0.97
Upside: +106.19%
BioMarin Pharmaceutical
Dec 3, 2025
Downgrades: Market Perform
Price Target: $82 → $60
Current: $61.12
Upside: -1.83%
Aurinia Pharmaceuticals
Dec 3, 2025
Downgrades: Market Perform
Price Target: $15 → $16
Current: $14.32
Upside: +11.73%
uniQure
Nov 10, 2025
Maintains: Outperform
Price Target: $68 → $60
Current: $14.27
Upside: +320.46%
Monopar Therapeutics
Nov 10, 2025
Initiates: Outperform
Price Target: $115
Current: $57.47
Upside: +100.10%
Sep 29, 2025
Maintains: Outperform
Price Target: $80 → $88
Current: $38.23
Upside: +130.19%
Sep 9, 2025
Maintains: Market Perform
Price Target: $12 → $15
Current: $16.71
Upside: -10.23%
Jul 7, 2025
Maintains: Outperform
Price Target: $18 → $20
Current: $16.23
Upside: +23.23%
Jun 10, 2025
Maintains: Outperform
Price Target: $100 → $115
Current: $140.13
Upside: -17.93%
May 23, 2025
Upgrades: Outperform
Price Target: $4 → $12
Current: $8.17
Upside: +46.88%
Feb 25, 2025
Initiates: Outperform
Price Target: $28
Current: $44.83
Upside: -37.54%
Oct 11, 2024
Maintains: Outperform
Price Target: $20 → $40
Current: $27.24
Upside: +46.84%
Jul 3, 2024
Upgrades: Outperform
Price Target: n/a
Current: $2.85
Upside: -
Jun 24, 2024
Upgrades: Outperform
Price Target: $12
Current: $6.75
Upside: +77.78%
Jun 20, 2024
Maintains: Outperform
Price Target: $6 → $8
Current: $0.39
Upside: +1,929.94%
Mar 17, 2023
Initiates: Market Perform
Price Target: $48
Current: $62.82
Upside: -23.59%
Feb 3, 2023
Maintains: Outperform
Price Target: $20 → $18
Current: $25.91
Upside: -30.53%
Feb 3, 2023
Maintains: Market Perform
Price Target: $33 → $34
Current: $74.04
Upside: -54.08%
Jan 17, 2023
Maintains: Outperform
Price Target: $148 → $163
Current: $240.65
Upside: -32.27%
Nov 10, 2022
Maintains: Outperform
Price Target: $40 → $33
Current: $5.69
Upside: +480.47%
Aug 5, 2022
Downgrades: Market Perform
Price Target: $64 → $52
Current: $10.16
Upside: +411.81%
May 12, 2022
Maintains: Outperform
Price Target: $34 → $30
Current: $27.82
Upside: +7.84%
May 5, 2022
Maintains: Outperform
Price Target: $50 → $30
Current: $92.09
Upside: -67.42%
Sep 26, 2017
Maintains: Outperform
Price Target: $10 → $12
Current: $1.78
Upside: +574.16%